THE INDEPENDENT RESEARCH REGISTRY FOR FOOD, NUTRITION AND HEALTH

 

Stay Connected
Join our global network and receive exclusive updates about the Research Registry.
 
   
 
 

Clinical Nutrition

The Clinical Nutrition special collection aims to advance our understanding of the role of nutrition in clinical practice. We invite submissions that investigate the efficacy of nutritional interventions in improving clinical outcomes, optimising patient care, and enhancing quality of life for individuals with acute or chronic medical conditions.
 

To filter by Category, Study Status, Study Type and Study Location, please go to Advanced Search.

Prevalence of Polypharmacy and Associated Side Effects In Individuals with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-analysis

Details
Category: Clinical Nutrition
Hits: 14
ID: 155
  • Study Status: Completed
  • Study Type: Review
  • Study Location: Global

Title
Prevalence of Polypharmacy and Associated Side Effects In Individuals with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-analysis

Principal Investigator
Sarah Armes, Jenneffer Tibaes, Ramya Rajaram, Mark Ruddock, Mary Jo Kurth, Peter Fitzgerald, Rajna Golubic, Sumantra Ray

Affiliation

  1. NNEdPro Global Institute for Food, Nutrition and Health, Cambridge, UK

  2. Randox Health, Crumlin, UK

  3. Randox Laboratories Ltd, Clinical Studies Group, UK

  4. School of Biomedical Sciences, Ulster University, UK

Start Date
01/06/2024

End Date
19/03/2025

Study Objective
To evaluate the prevalence of polypharmacy, associated side effects, and its effect on quality of life (QoL) and clinical outcomes in individuals diagnosed with MASLD.

Short Abstract
This systematic review focuses on MASLD, a chronic condition with frequent polypharmacy. It evaluated six studies (five in meta-analysis, n=153,855), finding polypharmacy prevalence from 25% to 89%, with pooled prevalence at 65%. Common medications were associated with adverse outcomes like hepatic encephalopathy, reduced QoL, and disease progression. Interventions like deprescribing and better medication management are recommended.

Study Design
Systematic Review

Population
Adults (18+) diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease

Sample Size
153,855 participants across six included studies (five in meta-analysis)

Inclusion Criteria
RCTs, quasi-RCTs, non-randomised trials, cohort, or case-control studies on MASLD adults

Exclusion Criteria
Pediatric studies, early terminated trials, studies without original data (e.g., reviews, abstracts)

Intervention/Exposure
Polypharmacy

Outcome Measures
Primary: Prevalence of polypharmacy
Secondary: Medication types, side effects, hospitalisation, QoL, liver function, disease progression, mortality

Funding Source
Randox Health

Collaborating Institutions
Randox Health

Ethics Approval
N/A

Publication Status
Not yet published

Keywords
Polypharmacy, Metabolic Dysfunction-Associated Steatotic Liver Disease

Data Collection Methods
Systematic literature search

Primary Data Availability
Not specified

Contact Information
This email address is being protected from spambots. You need JavaScript enabled to view it.